Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...

Eli Lilly has filed lawsuits ... solutions for individual patient needs. The legal action also questions the safety of the compounded drugs and challenges whether the defendants are violating ...

Lilly sues four telehealth firms for unauthorized compounding of Mounjaro and Zepbound. 2. GLP 1 drugs remain in high demand ...

Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo ...

Eli Lilly has raised its revenue guidance for ... "While weekly prescription volume was volatile in the first half of the year due to challenges fulfilling high demand, our progress on supply ...

He said that is "likely to challenge growth in the end of the decade," especially as Eli Lilly's own obesity pill impresses investors and inches closer to entering the market. Unlike oral ...

Eli Lilly (NYSE:LLY) is a pharmaceutical titan ... despite competitive and regulatory challenges. The pharma giant plans submissions to the Food & Drug Administration for obesity in late 2025 ...

You can reach Katie on Signal at palmer.01. Amid ongoing battles over alternate supplies of blockbuster weight loss drugs, Eli Lilly filed new lawsuits against four telehealth firms and their ...